Effect of Calcium Channel Antagonists and Sex on Bone Metabolism in Aged Brown Norway Rats by Kidd, Brent
Effect of Calcium Channel Antagonists and Sex on 
Bone Metabolism in Aged Brown Norway Rats 
A Thesis 
Presented to 
the Faculty of the College of Science & Technology 
Morehead State University 
In Partial Fulfillment 
of the Requirements for the Degree 
Master of Science 
f 
by 
Brent Kidd 
April 2007 
ms (,k THESES 
57'J.'-f 
K '--i !oe 
Accepted by the faculty of the College of Science and Technology, 
Morehead State University, in partial fulfillment of the requirements for the 
Master of Science Degree. 
Master's Committee: 
Date 
Effect of Calcium Channel Antagonists and Sex on 
Bone Metabolism in Aged Brown Norway Rats 
Brent Kidd, M. S. 
Morehead State University, 2007 
Director of Thesi✓.--" t,.-2--- ,:::. ~ [ 
Calcium channels are a potential point of regulation for skeletal remodeling and 
calcium channel antagonists are utilized therapeutically and experimentally to 
decrease the influx of calcium into cells by blocking voltage-regulated L-type 
calcium channels. Previous experimental evidence has suggested that calcium 
channel antagonists decrease osteoblastic activity, thus decreasing the activity of the 
bone forming cells in aged animals at a time when bone formation is already 
exceeded by bone resorption, exacerbating the situation. Therefore, the established 
principle that bone formation decreases following the attainment of peak bone mass, 
establishes the need for a more comprehensive understanding of the action calcium 
channel antagonists have on bone turnover. The experimental design in this research 
used six month old male and female Brown Norway Rats in order to compare the 
effects of sex and calcium channel antagonists on blood pressure and bone turnover 
from both the bone fluid and calcified compartments. In order to evaluate the 
positive or negative impact of various calcium channel antagonists on bone loss, bone 
resorption parameters were compared between normal males and females, to those 
receiving the calcium channel antagonists diltiazem, nifedipine, or verapamil. The 
model utilized to study bone turnover was the pharmacokinetic loss of the tracer 3H-
tetracycline, a compound deposited in the active mineralization front and freely 
released in urine throughout the experimental period. The turnover of 3H-tetracycline 
was also studied in the bone fluid compartment by leeching the label from designated 
bones of the axial and appendicular skeleton oflabeled rats. The results from these 
two types of experimentation clearly suggest the presence of a rapidly exchangeable 
pool (bone fluid compartment) and a stable pool ( calcified compartment). The impact 
of the calcium channel antagonists on pool turnover in each of these highly regulated 
calcium pools is significant in both male and female treatment groups. 
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INTRODUCTION 
This project was designed to enhance the understanding of the action elicited by 
calcium channel antagonists on bone resorption, through the utilization of organismal 
techniques. The holistic protocols and the subsequent analysis will focus on the 
effects that calcium channel antagonists have on skeletal physiology in both male and 
female aged Brown Norway Rats. The proposed study will examine the hypothesis 
that bone resorption is regulated by the influx of Ca* ions and since calcium channel 
antagonists are known to block the transport of calcium in cardiovascular tissue we 
would expect these drugs to have a similar impact on calcium movement in skeletal 
tissue. The specific objectives outlined in the experimental design and analysis were 
twofold. First, to determine what aspects of bone resorption are affected by calcium 
channel antagonists in both male and female aged rats through the use of the 3H-
tetracycline rat model, and second to determine the feasibility of extracting 3H-
tetracycline from the bone fluid compartment, and if these values correlate with data 
obtained for the bone fluid compartment during the metabolic studies. 
Role of Estrogen in the Regulation of Bone Resorption 
Osteoporosis has been viewed as a primary disease among women for over 100 
years (Brun, 1882). Albright, et.al., (1940 and 1947) first linked osteoporosis to 
estrogen in a series of papers indicating the prevalence of negative calcium balance 
among osteoporotic women and demonstrated its reversal in osteoporotic 
postmenopausal women through the use of estrogen therapy. A number of 
subsequent studies have indicated that women show a gradual reduction in bone mass 
from about the age of 20 (Recker et al, 1992 and Riggs et al, 1985 and 1982,) with 
accelerated losses at menopause (Jasani et al, 1965, Lindsay et al, 1992, and Nordin et 
al, 1966). Postmenopausal changes in the skeleton include both bone loss and 
changes in its architecture. A major characteristic of bone loss following loss of 
ovarian function is the widespread loss of intertrabecular connections, which may 
significantly decrease mechanical strength (Dempster et al, 1986). Surprisingly, even 
the gross nature of the changes in bone cell activity that lead to these alterations in 
postmenopausal bone is not certain. There clearly is increased activation of 
resorption with new remodeling sites leading to an increased amount of surface 
remodeled (Parafit, 1984 ). However, it is also suggested that the qualitative nature of 
osteoclast resorption (deeper resorption cavities) (Parafit et al, 1983 and 1984), the 
uncoupling of resorption/formation (Ivey et al, 1981) or simply decreased osteoblast 
formation of bone (Lips et al, 1978) may be principal causes of bone loss in estrogen 
deficiency. 
The action of estrogen on skeletal physiology has been known for quite some time 
but the cellular basis for its action is uncertain. Because there is increased 
frequency of activation of new remodeling sites after ovariectomy and menopause, it 
has been proposed that estrogen may act to prevent contraction of osteoblasts lining 
the bone surfaces (Rodan and Martin, 1981) leading to exposed bone surface and 
initiation of resorption by osteoclasts. Research by Earnst and Rodan (1989) and 
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Gray et al (1998) on estrogen-mediated proliferation of osteoblasts in culture 
suggested that the steroid acted directly on this bone cell type to ultimately inhibit 
osteoclasts. However, it should be noted that estrogens have only been shown to be 
effective in decreasing bone resorption at high doses under in vitro conditions (Jilka 
et al, 1992, Manolagsas and Jilka, 1992, and Pacifici et al, 1991). Others have 
suggested that estrogen influences bone remodeling indirectly through the induction 
of other mediator compounds in peripheral tissues (Pacifici et al, 1991) or in bone 
cells (Jilka et al, 1992, and Manolagsas and Jilka, 1992). In particularly elegant 
work, Poli, et.al., (1994) have shown that interleukin-6 deficient transgenic mice were 
protected from bone loss by estrogen deficiency, supporting the concept that estrogen 
could act to suppress active mediators of bone resorption. This latter study 
underscores the potential complexity of the interactions that may exist in the pathway 
employed by estrogen regulation of bone mineral metabolism and may explain the 
confusion of information derived from bone and cell culture studies. 
Role of Cellular Calcium in the Regulation of Bone Resorption 
Bone metabolism is invariably correlated with calcium transport. Therefore, 
calcium channels are a potential point of regulation for skeletal remodeling. In an 
attempt to address the role of calcium transport, calcium channel antagonists can be 
employed to probe the role of calcium channels in this process. These antagonists are 
commonly utilized therapeutically for their blood pressure lowering properties and 
experimentally to decrease the influx of calcium into cells by blocking voltage-
3 
regulated calcium channels. Calcium channel antagonists present heterogeneity of 
structure and variable pharmacologic function, these three principle classes of 
calcium channel antagonists associate with different regions of the L-type calcium 
channel (Epstein, 2002). A number of studies have also indicated that representatives 
from each of the major classes of calcium channel blockers (verapamil, nifedipine, 
and diltiazem) may also influence skeletal bone metabolism. For example, it has 
been demonstrated that calcium channel blockage decreased both parathyroid 
hormone (Hermann- Erlee et al, 1977) and 1,25-hydroxyvitamin D3-induced (Lerner 
and Gustafson, 1982 and Ly et al, 1985) bone resorption in vitro. Verapamil has been 
shown to increase bone loss in uremic rats (Chagnac et al, 1989) and there is 
convincing evidence that calcium channel blockers have a direct inhibitory effect on 
osteoblast function (Kim et al, 1991). More recently, it has been shown that 
epidermal growth factor-induced osteoblastic cell proliferation is caused by an 
increase in intracellular calcium, primarily due to extracellular calcium influx (Loza 
et al, 1995). These findings strongly suggest that a number of regulatory molecules 
that increase bone resorption may utilize the elevation of intracellular calcium as one 
element in the transduction pathway. However, it has been shown that 17~-estradiol 
inhibited calcium influx and intracellular release of calcium by thrombaxane A2 in 
coronary artery smooth (Han et al, 1995) and reduced systolic intracellular calcium 
concentration through the inhibition of calcium influx in cardiac myocytes (Jiang et 
al, 1992). Hence, it appears that estrogen could act directly or indirectly (through 
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secondary mediators) to attenuate resorption activity through the inhibition of calcium 
influx in opposition to the action of other regulatory agents tending to increase bone 
resorption. 
History of the 3H-Tetracycline Rat Model 
The laboratory rat exhibits the same physiological mechanisms for bone growth 
modeling and remodeling as seen in humans (Frost and Jee, 1992). Both trabecular 
and cortical bone masses increase during growth while bone remodeling in the rat 
results in the removal of bone from the endocortical and trabecular envelopes 
(Kimmel and Jee, 1980 and Li et al, 1991). Unlike humans, rats possess few primary 
Haversian systems and few, or no, secondary Haversian systems. However, this may 
be viewed as a positive feature of the model because of the relative lack of 
remodeling in the intracortical envelope accents the resorptive losses from the 
endocortical and trabecular envelopes, which are the types of remodeling, observed in 
various human bone diseases. Relevant to the present proposal, the ovariectomized 
rat provides a recognized model of estrogen deficiency osteoporosis. 
In vitro systems cannot adequately represent the multiple interacting hormonal 
and mechanical influences on bone metabolism therefore, an in vivo model utilizing 
whole animals is more ideal. In this regard, the 3H-tetracycline rat model enables the 
quantitative measurement of bone resorption with time. 3H-tetracycline possesses the 
major characteristics of an excellent label for use in the evaluation of bone resorption. 
This compound avidly binds to bone at the mineralization front and becomes widely 
distributed throughout the skeleton (Bloomquist and Hanngren, 1968 and Kohn, 
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1961). The loss of 3H-tetracycline from bone is irreversible such that the compound 
is unavailable for reutilization (Frost, 1965). The release of tetracycline from bone 
has been shown to reflect both the destruction of the bone matrix and the loss of 
inorganic material and is, thus, physiologically relevant and a direct indicator of bone 
resorption (Klein et al, 1983). 3H-tetracycline is extremely stable both in vivo (Kelley 
and Buyske, 1969) and in vitro (Chen and Klein, 1978) and the tissue concentration is 
directly related to calcium content (Bloomquist and Hanngren, 1968). Renal 
excretion of the compound is very efficient with a circulatory half-life of2.8 hours 
(Raghuram et al, 1982) and complete elimination from soft tissues within 24 hours in 
the rat (Bloomquist and Hanngren, 1968). Limitations on the use of tetracycline as a 
marker for bone resorption include its restriction to animals with normal renal 
function and an inability to accurately monitor resorption during intervals of rapid 
change. In summary, the combination of 3H-tetracycline affinity for bone, its 
physiologically relevant release from bone, its rapid clearance from circulation and 
soft tissue, and only minor restrictions on its use highly recommends this compound 
for the noninvasive assessment of bone resorption. 
Klein and associates (Klein et al, 1983 and Li et al, 1989) pioneered the use of the 
3H-tetracycline/rat model and provided ground-breaking work in the study of age 
related changes in bone resorption. They concluded that the loss of 3H-tetracycline in 
urine was described by a monoexponential curve indicating loss from a single 
compartment. However, more recent studies conducted by DeMoss and colleagues 
have resulted in a number of modifications to the various protocols used in this 
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method which greatly improves its utility in the quantitative evaluation of skeletal 
resorption in vivo (DeMoss and Wright, 1997 and 1998, Geng et al, 2000, Wright et 
al, 2000, and Wright and DeMoss, 2000). However, the whole animal model does 
not allow the elucidation of the mechanisms involved in bone resorption at the 
cellular or molecular level, as an in vitro model or analysis of gene activity could. 
Therefore, holistic and molecular models will be necessary to elucidate the 
mechanisms of regulated bone metabolism. 
Refinement of 3H-tetracycline Model 
DeMoss et al refined the 3H-tetracycline rat model and improved the quantitative 
assessment of skeletal resorption (DeMoss and Wright, 1997 and 1998, Geng et al, 
2000, Wright et al, 2000, and Wright and DeMoss, 2000). Utilizing Table Curve 2D 
Automated Curve Fitting Software in analyses to determine best fit equations 
(DeMoss and Wright, 1998), established that the urinary loss of 3H-tetracycline from 
day 2 through day 35 is best described by a double exponential equation indicating a 
two component model comprised of two distinct bone calcium pools. This analysis 
further provided the determination of: y-intercept, the uncomplicated rate oflabel loss 
at time zero with the bone pool fully labeled; t, the time constant for depletion of the 
pool and; (Cy-intercept (t x 5))/2), the size of the labeled pool. 
As one major modification of the method previously employed with the 3H-
tetracycline rat model, the labeling protocol was shortened so that isotope injections 
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were administered for only two weeks prior to urinary loss measurements. It may be 
argued that animals must be injected from 1 to 3 weeks of age through the entire 
interval prior to the start of measurements to ensure a complete labeling of deep bone 
during intervals ofrapid skeletal growth (Klein et al, 1983 and Li et al, 1989). Thus, 
DeMoss and Wright (1998) demonstrated that the 2-week labeling interval was 
adequate to label areas of active bone resorption in mature animals . Moreover, the 2-
week labeling procedure was found to result in urinary loss curves that were similar 
to those that were labeled from birth to 8 weeks of age (DeMoss and Wright, 1998). 
Although intuitively one may wish for a complete labeling of bone throughout, the 
real objective of the labeling procedure is to label those areas of active bone 
metabolism. The rat, however, does not undergo intracortical remodeling (few or no 
secondary Haversian Systems) so that bone turnover is confined to surface areas. 
DeMoss and colleagues (DeMoss and Wright, 1997 and 1998, Geng et al, 2000, 
Wright et al, 2000, and Wright and DeMoss, 2000) data suggests that, because deep 
bone resorption is quiescent, it is not essential to label deep bone and the 2-week 
protocol employed is adequate to thoroughly label the relevant areas of bone 
turnover. Moreover, the analysis employed bases comparisons between groups not 
only on the rate oflabel efflux from the skeleton but also on the pool size and the rate 
of depletion of the labeled pool. It can, therefore, be argued that labeling of the 
available bone surface sites for tetracycline binding provides an accurate measure of 
relative resorption activities between groups. 
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In the past, tetracycline release from the skeleton was expressed on the basis of 
body weight or as total DPM excreted. In order to place results on an appropriate 
basis DeMoss and Wright (1997) sacrificed 4 to 24-week old male and female rats 
from three strains (Sprague Dawley, Wistar Kyoto, Spontaneously Hypertensive 
Rats) specifically for the determination of dry skeletal weight and total dry skeletal 
calcium content. This work clearly demonstrated the relationship between body 
weight and dry skeletal mass is linear within groups but that significant differences 
exist between strain and sexes. Most interestingly, it was found that the ratio of 
skeletal mass to body weight in mature females was 30% to 40% greater than in 
males. Because this relative increase in skeletal development cannot be due to 
increased demand for mechanical support in the smaller female, these results have a 
number of interesting implications regarding the regulation of bone formation and 
skeletal maintenance in mature, ovary-intact females. These findings enabled the 
development of regression equations for the calculation of whole skeletal mass 
following the determination of body weight (DeMoss and Wright, 1997). The 
relationship between skeletal mass and calcium content indicate that the degree of 
calcification per gram of dry skeletal mass or total skeletal calcium would be 
appropriate parameters for the expression of 3H-tetracycline loss in urine (DeMoss 
and Wright, 1997). However, body weight is an inappropriate parameter due to 
significant gender and strain related differences in the ratio of skeletal mass to body 
weight. It may be argued that resorption data cannot be expressed in dpm/skeletal 
weight because of growth, which will show a loss in activity due to dilution in older, 
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larger animals (Li et al., 1989). On the other hand, if the same level oflabel loss is 
observed in an animal half the size of another, one may suspect that the relative rate 
of bone turnover in the smaller animal is high compared to that of the large animal. 
In light of DeMoss and Wrights (1998) findings that the ratio of skeletal weight is 
significantly different between sexes and among rat strains, it is necessary to express 
resorption data on the basis of skeletal weight for quantitative comparisons between 
groups. In addition, regression analysis has been utilized to further define the 
relationships among body weight, whole skeleton bone resorption, and the 
development of skeletal mass. DeMoss' results indicated that skeletal development 
(%bodyweight) of slowly growing, 24 week-old rats consisted of two major 
components, one directly and one inversely related to body weight. It was further 
noted that the skeletal resorption rate was inversely correlated to body weight and 
directly related to skeletal development, suggesting that whole skeleton bone 
resorption and formation were highly correlated in the slowly growing animal. A 
third small component of skeletal development identified in the analysis of data from 
24 week-old animals, showed no direct relationship to either body weight or 
resorptive activity. The model presented enables the separation of skeletal mass into 
major components, which may represent mechanically and metabolically driven bone 
formation (Wright et al, 2000). 
In order to further characterize the two bone calcium pools reflected in the loss of 
3H-tetracycline in urine, a study conducted by DeMoss (unpublished) to monitor the 
loss oflabel from a selection of 12 individual bones removed at selected intervals 
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from rats injected with the isotope. The amount oflabel remaining in the bones was 
then determined by extracting the compound with 0.5N HCL for liquid scintillation 
counting. The best-fit analysis of these data indicated that the label loss was 
described by a single exponential with an offset indicating the presence of a 
resorbable and a nonresorbable pool. Because two resorbable compartments were 
identified from 3H-tetracycline urinary loss curves while only one was obtained from 
the 3H-tetracycline content of individual's bones, it was of interest to determine if 
significant label loss occurred during the processing of individual bones. In 
subsequent experiments, it was found that significant loss oflabel did occur during a 
water wash used prior to the HCL extraction. It was then calculated that 23.2% of the 
total label in individual's bones was located in a water-soluble pool, 40.3% in a 
resorbable but water-insoluble pool, and that the remaining 36.5% was not resorbed. 
Assuming that 36.5% of the skeletal 3H-tetracycline was nonresorbable, it was further 
calculated that the rapidly depleted and the slowly depleted components of the urinary 
label loss curves represented 25.3 and 38.2% of total label, respectively. DeMoss and 
colleagues concluded that the rapidly depleted pool of urinary 3H-tertacycline loss 
represents calcium loss from a water soluble, amorphous, bone associated calcium 
compartment (bone fluid); whereas, the slowly depleted component of urinary loss 
reflects the active resorption of calcified bone (Wright and DeMoss, 2000 and Wright 
et al., 2000). 
In previous use of the model, it has been the standard procedure to eliminate the 
first 7 days of urine tetracycline losses from analysis (Li et al., 1989) because of the 
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potential for contamination of bone label losses with that from soft tissues. However, 
there are at least 4 lines of evidence indicating that DeMoss and colleagues 
contention of tetracycline loss from a rapidly depleted, water-soluble bone 
compartment has merit and is not related to soft tissue losses of the compound. First, 
direct measurements of tissue tetracycline-associated fluorescence and radioactivity 
indicated that even soft tissues of the sub lingual gland and parathyroid gland which 
accumulate tetracycline to a remarkable degree, are devoid of the compound by 24 
hours (Bloomquist and Hanngren, 1968). Secondly, it was determined that nearly 
25% of the tetracycline label of individual bones is removed by simply soaking whole 
bones in water for as little as 6 hours (DeMoss, unpublished). Third, various 
estimates indicate that up to 90% of the label recovered in urine occurs in the frrst 24 
hours (Li et al., 1989). This level of isotope loss clearly does not fit the double-
exponential regression equation for what is referred to as the fast component of 
urinary loss (bone fluid compartment). Finally, the data indicates that the rate oflabel 
loss from the fast compartment is increased by decreasing the calcium content within 
the diet (Geng et al., 2000). There is little reason to believe that this experimental 
manipulation would affect soft tissues depletion; whereas, the resulting challenge to 
calcium homeostasis would be expected to increase the loss oflabel from an 
amorphous calcium component of bone. 
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Bone Fluid Compartments Role in Ca++ Homeostasis 
The skeleton serves as a storehouse for Ca++ and Pol-. Approximately 99% of 
the bodies' total calcium is stored in bone and is exchanged between bone mineral, a 
labile calcium pool, and the extracellular fluid daily as bone undergoes remodeling 
(Goodman, 1996 and Sherwood, 2007). This Ca++ is essential in many of the bodies' 
mechanisms and can be found in two separate compartments in bone, the labile pool 
which consists of bone fluid (amorphous) and the stable pool which is composed of 
calcified bone (Sherwood, 2007). DeMoss and colleagues have published several 
papers utilizing a modified analysis of the 3H-tetracycline rat model for bone 
resorption that reinforces the existence of the two distinct bone calcium pools, one of 
which is a water-soluble pool (DeMoss and Wright, 1997 and 1998, Geng et al, 2000, 
Wright et al, 2000, and Wright and DeMoss, 2000). This water-soluble pool 
composed of bone fluid can act as an immediate source of Ca++ to help maintain a 
homeostatically regulated plasma concentration of Ca++_ This balance is maintained 
mainly by the hormone parathyroid hormone (PTH) which can facilitate both 
immediate and chronic effects on Ca++ homeostasis. Morphological studies suggest 
that this system responds within several minutes of exposure to PTH (Davis et al, 
1975, Harrison and Fraser, 1960, and Matthews and Talmage, 1981), thus providing 
the body with an extracellular fluid buffering mechanism of rapid proportion (Aarden 
et al, 1994, Matthews et al, 1980, and Menton et al, 1984). Therefore, the bone fluid 
compartment plays a critical role in reestablishing the plasma Ca++ concentration 
during periods ofhypocalcemia. However, when the body undergoes a chronic 
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period ofhypocalcemia, PTH will act on bone stimulating the bone resorption process 
that leads to the release of Ca++ from the bone itself. This system helps explain how 
the destruction of calcified bone is involved in the maintenance of the plasma Ca++ 
concentration. 
Bone Degradation Markers 
The organic matrix of bone consists of approximately 90% type I collagen (Seibel 
and Woitge, 1999). Trifunctional pyridinium crosslinks - pyridinoline (Pyd) or 
deoxypyridinoline (Dpd) - form between hydroxylysine or lysine residues at the C-
and N-telopeptide ends of one collagen molecule and the helical portion of a 
neighboring molecule during collagen maturation (Seibel et al, 1992 and 1999). This 
crosslinking provides structural rigidity to the collagen fibril. Osteoclastic 
degradation of bone collagen releases the crosslinks into circulation, and they are 
eventually excreted in urine. Though the crosslinks are present in a number of 
tissues, the molar ratio of Pyd and Dpd in urine is very similar to that in bone, 
indicating that urinary concentrations of both are derived mainly from bone. Dpd in 
particular, with a more limited tissue distribution than Pyd, is derived almost 
exclusively from bone (Delmas, 1995, Eastell et al, 1997, James et al 1996, Robins, 
1995, Roux et al, 1995, and Seibel et al, 1992 and 1999). As products of collagen 
maturation, they cannot be reused in new collagen synthesis, nor are they further 
metabolized (Delmas, 1995, Seibel and Woitge, 1999, and Robins, 1995). Of the 
total pool of urinary Dpd/Pyd, approximately 40-45% is free and the remainder is 
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bound to peptides (Seibel et al, 1992 and Robins, 1995). The total excretion of 
Dpd/Pyd measured by high performance liquid chromatography (HPLC) is correlated 
with histomorphometric resorption indices of iliac crest biopsies, and with 
radioisotope kinetic estimates of whole body bone resorption (Eastell et al, 1997 and 
Roux et al, 1995). Free Dpd/Pyd can be measured both by HPLC and by a highly 
specific enzyme immunoassay (Robins et al, 1994). Free Dpd levels measured by 
immunoassay are highly correlated with free or total Dpd/Pyd measured by HPLC 
(Robins et al, 1994). Increased urinary levels ofDpd are observed among 
postmenopausal women compared to premenopausal women and are associated with 
rapid bone loss and an increased risk of hip fracture (Gamero et al, 1996, Hesley et al, 
1998, Ross and Knowlton, 1998, and V anDaele et al, 1996). Increased Dpd excretion 
is seen in a number of conditions characterized by excessive bone resorption 
including osteoporosis, Paget' s disease, hyperparathyroidism, thyrotoxicosis, 
malignant hypercalcemia, and metastatic cancer (Delmas, 1995, Seibel et al, 1992, 
and Robins et al, 1994). Dpd/Pyd levels decrease rapidly following antiresorptive 
therapy in a dose-dependent manner (Delmas, 1995, Gamero et al, 1994, and Hesley 
et al, 1998). These short-term changes are inversely correlated with long-term 
changes in bone mineral density (Gamero et al, 1994 and Hesley et al, 1998). 
Elevated pyridinium crosslink levels, particularly of Pyd, are also seen in rheumatoid 
arthritis and osteoarthritis and correlate with disease activity (Gerrits et al, 1995, 
Gough et al, 1994, Seibel et al, 1989, and Thompson et al 1992). The organic matrix 
of bone contains approximately 90% type I collagen, a helical, heterotrimeric 
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molecule comprising two al chains and one u2 chain (Seibel and Woitge, 1999). A 
number of markers of collagen degradation have been described, including modified 
amino acids, peptides, and intermolecular crosslinks (Seibel and Woitge, 1999). The 
pyridinium crosslinks and related amino- and carboxyterminal telopeptides of type I 
collagen have been well validated as markers of bone resorption (Miller et al, 1999 
and Seibel and Woitge, 1999). These markers reflect degradation of the nonhelical 
end region of collagen and that modified amino acids are distributed throughout the 
molecule. No marker has enabled assessment of degradation of the helical region that 
makes up the bulk of type I collagen. Ju et al (1997) identified a 14 amino acid type I 
collagen helical region peptide that was isolated from the urine of an individual with 
Paget's disease and developed a specific competitive enzyme immunoassay to 
measure it. Increased urinary levels of helical peptide ul(I) 620-633 were observed 
in postmenopausal women with osteoporosis and in individuals with Paget' s disease, 
conditions characterized by elevated bone collagen degradation (Ju et al, 1997). 
Helical peptide levels decreased following therapy with estrogen or bisphosphonate 
reflecting the antiresorptive effect of these agents (Ju et al, 1997 and Ju et al, 1998). 
Clinical Significance 
Drugs classified as calcium channel antagonists have been in use in clinical 
medicine since the 1960's and are among the most frequently prescribed drugs for the 
treatment of cardiovascular disease (Abernathy and Schwartz, 1999). Although 
chemically diverse, these drugs share the common property of inhibiting the action of 
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the voltage-gated L-type calcium channels. The ability of these drugs to decrease 
smooth muscle and myocardial contractility results in both clinically desirable 
antihypertensive and antianginal effects. The established principle of decreasing 
bone formation resulting in increasing bone resorption following the attainment of 
peak bone mass illustrates the need for a more comprehensive understanding of the 
action of these drugs. Experimental evidence suggests that calcium channel 
antagonists decrease osteoblastic activity, thus decreasing the activity of the bone 
forming cells at a time when bone formation is already exceeded by bone resorption, 
thus exacerbating the situation. Clinical medicine is treating one ailment and may 
possibly be causing another. The benefits of this type of treatment for cardiovascular 
disease may significantly outweigh the adverse effects on the skeletal system. 
However, these studies may shed some light on the increase in osteoporosis over the 
past twenty years, particularly within the male population instead of simply 
attributing it to a longer life span. It is known that there is about a ten-year lag in the 
age-related rise in cardiovascular mortality in women compared to men (Lindsay and 
Cosman, 2001). This difference is likely attributed to estrogens protective action 
prior to menopause and hormonal replacement therapy following menopause. Lastly, 
this investigation will hopefully provide insight into which class or classes of calcium 
channel antagonists decreases resorptive activity and functions through a mechanism 
involving estrogenic effects while at the same time providing maximal cardiovascular 
protection, improving the physician's decision during drug selection and highlighting 
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those antagonists which are beneficial to the cardiovascular system but have potential 
detrimental effects on the skeletal system. 
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METHODS 
Animals: 
All animal protocols outlined herein were approved by Morehead State University's 
Institutional Animal Care and Use Committee (IACUC). Prior to and during the 
experimental protocol, all rats were maintained in rooms at 23°C ± 2° on a 12-hour 
light/dark photoperiod with free access to tap water and a diet low in phytoestrogens 
(Harlen Tekland). The strain of rats used in this study were 24-week old male and 
female Brown Norway Rats purchased from Harlan Laboratories through the National 
Institute of Aging. This rat was selected as a readily available model widely used by 
other investigators as a model for postmenopausal osteoporosis in women. The 
number of animals to be employed will reflect that which allows statistical evaluation 
of the data from the outlined experimentation. The animals were housed in the 
Animal Care Facility in the Department of Biological and Environmental Science. 
Food consumption, urinary output, and body weight were continuously assessed 
while the animals were housed in metabolic chambers. Veterinary care was provided 
by Dr. Philip Prater, DVM. 
Blood Pressure Analysis: 
Blood pressure was monitored non-invasively in rats via Volume Pressure Recording 
(VPR). VPR uses a tail sensor cuff to measure as many as seven different 
physiological parameters; systolic blood pressure, diastolic blood pressure, mean tail 
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pressure, heart rate, blood volume, blood flow, and tail temperature. Filtering or post 
processing software calculations are not required. Blood pressure analysis was 
conducted using Kent Scientifics' VPR hardware and software. The VPR acquisition 
software is specially designed to automatically measure and display in real-time, all 
of the non-invasive blood pressure parameters and waveforms. The animals were 
maintained in cages with free access to tap water and a diet low in phytoestrogens 
(Harlen Tekland). The animals utilized in the study were 20 wk old Brown Norway 
Rats (Figure 1 ). The animals initially underwent a four week training period allowing 
them to acclimate to the blood pressure acquisition procedure. During this time 
period each animal was exposed to multiple runs of the blood pressure acquisition 
process (twice a week), which included the preheating process and being restrained 
and cuffed with the associated hardware. The animals were divided into groups in 
order to allow statistical comparison, these treatment groups included; control (male 
and female), ovariectomized females, diltiazem (male and female), nifedipine (male 
and female), and verapamil (male and female). At the end of the four week training 
period ( animals now 6 months of age) each animal's blood pressure was taken twice a 
week for three weeks to provide a baseline blood pressure. On week four of blood 
pressure acquisition, the animal's receiving calcium channel antagonists were 
administered a previously determined therapeutic dose ( diltiazem 8 mg/kg body 
weight, nifedipine 2 mg/kg body weight, and verapamil 8 mg/kg body weight) (Sigma 
Aldrich Chemicals) via a daily subcutaneous injection. Blood pressure readings were 
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Figure 1. Protocol Outline for Blood Pressure Analysis 
21 
Verapamil 
(8mg/kg) 
continued for each animal twice a week for an additional three weeks once they 
received their initial treatment dose. 
3H-Tetracycline Protocol for Measurement of Whole Skeleton Bone Resorption: 
As illustrated in Figure 2, whole animal measurement of bone resorption was 
obtained by labeling the rat skeleton with 3H-tetracycline (PerkinElmer). The male 
and female Brown Norway Rats were five months of age upon arrival and were 
maintained in metabolic chambers with free access to tap water and a diet low in 
phytoestrogens (Harlen Tekland). Each animal underwent a labeling period involving 
six subcutaneous injections (one every third day) of 3H-tetracycline dissolved in 
0.05M HCl containing ascorbic acid as a reducing agent. Each rat received a total of 
36µCi during the labeling procedure and were six months of age at the conclusion of 
the labeling process. Following the administration of the final isotope injection, 
animals were broken into groups ( control, vehicle control, diltiazem, nifedipine, and 
verapamil). Animals in each group received a daily, subcutaneous injection of 
diltiazem 8 mg/kg body weight, nifedipine 2 mg/kg body weight, and verapamil 8 
mg/kg body weight, and urine was collected at 24-hour intervals for a period of 28 
days. Urine volume was determined each day and an 0.5 ml aliquot from each 
sample was combined with 10 ml of SXl 8-4 Scintiverse BD Cocktail (Fisher 
Scientific; Pittsburgh, PA) to determine 3H-tetracycline content by liquid scintillation 
spectrometry (Beckman Scintillation Counter). The 3H-tetracycline urinary loss 
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Figure 2. Protocol Outline of Metabolic Study 
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curve generated for each animal was analyzed by Table Curve 2D Automated Curve 
Fitting Software (SPSS INC.; Chicago, IL.) to determine the best fit equation. In 
previous experimentation, Wright and DeMoss (2000) have determined that the 
individual 3H-tetracycline loss curves were best represented by a double exponential 
equation (two-compartment model compromised of two exchangeable bone calcium 
pools). The use of this equation to analyze each curve provided the following 
parameters for each compartment: (1) the uncomplicated rate of label loss at time 
zero with the pool fully labeled; (2) the time constant required for >98% of the pool 
to be depleted; (3) the labeled pool size per gram dry skeletal mass; and ( 4) the total 
labeled pool size. In addition, a sample of urine from each day of the experimental 
protocol was saved and frozen, for future processing for the presence of various bone 
metabolic degradation markers once the holistic experimental process was completed. 
Dpd, Pyd, and Helical peptide levels will be corrected for differences in urine 
concentration and output by dividing by creatinine ( expressed as µg/mmol). 
Dry Skeletal Mass Determination: 
At the end of the metabolic protocol (Figure 2), skeletal mass was determined and 
analyzed as an indicator of imbalance between bone resorption and formation as 
indicated by the work ofDeMoss and Wright, 1997 and 1998 and Geng et al, 2000. 
Animals were euthanized via CO2 inhalation and body weights were recorded. 
Euthanized animals were skinned and disemboweled then dehydrated in a Fischer 
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Isotemp Oven. The dehydrated carcasses were then placed with Dermestid Beetle 
colonies (Dermestes maculates, Carolina Biological Supply Co., Burlington, N.C.) to 
remove the remaining tissues. Skeletons were then soaked in ethyl alcohol to kill 
Dermestid larva and then repeatedly washed in water, lyophilized (LABCONCO 
Freeze Dry System) and weighed to obtain dry skeletal weight. 
Organ Isotope Extraction: 
In order to detect the presence of the bone fluid compartment, 24 week old male and 
female Brown Norway Rats underwent an abbreviated (three injections, 72 hours 
apart) 3H-tetracycline labeling process 18µCi total (Figure 3). At the conclusion of 
the labeling protocol specific bones from both the axial and appendicular skeleton 
were removed from the animals at three different sacrifice intervals ( 48, 96, and 144 
hours) following the last isotope injection. Throughout the experimental period the 
animals were maintained as previously described under the metabolic study. The 
male and female animals were divided into groups of three for both control and 
nifedipine. The nifedipine group received a daily dose of 2 mg/kg body weight of 
nifedipine (Sigma Aldrich Chemicals) 24 hours after the last isotope injection. The 
animals were anesthetized via an LP. injection of sodium pentobarbital followed by 
exsanguination via a cardiac puncture. The cardiac puncture was performed in order 
to remove any or most of the isotope that may be in circulation. The animals were 
then skinned, disemboweled, and the following representative bones were removed 
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Figure 3. Protocol Outline for Organ Isotope Extraction 
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from the axial and appendicular skeleton: parietal, atlas, 2nd lumbar vertebrae, 2nd 
floating rib, ulna, humerus, tibia, and femur. One gram of skeletal muscle was also 
removed and utilized as a negative control. The bones were manually cleaned of as 
much tissue as possible and exposed to a series of dilutions in distilled water 
(leeching process) over a period of nine days. The dilution series consisted of three 
different distilled water dilutions, dilution one consisted of the axial bones being 
exposed to 5 ml while the skeletal muscle sample and bones of the appendicular 
skeleton were placed in 10 ml while dilutions two and three had reduced volumes by 
half for all specimens (2.5 ml for the axial and 5 ml for the appendicular and skeletal 
muscle tissue). The bones incubated in each dilution for a period of72 hours at 6°C 
with daily vortexing. A 0.5ml sample was removed from each dilution and analyzed 
for 3H-tetracycline content using liquid scintillation spectrometry. The bones were 
then lyophilized, weighed, and dissolved in a dilution series of 0.5M HCL to 
determine the amount of 3H-tetracycline label remaining in the calcified portion of 
each bone using liquid scintillation spectrometry. The dilution series for the acid was 
conducted in the same fashion as that for the distilled water outlined above with the 
exception of an additional dilution for the bones of the appendicular skeleton identical 
to the third dilution, in order to recover any excess isotope from the calcified 
compartment. A 0.5 ml aliquot was removed from each dilution and analyzed for 3H-
tetracycline content using liquid scintillation spectrometry. 
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Statistics: 
All data were compared utilizing an ANOV A (Statview for Windows, SAS Institute 
Inc.) to determine significant differences. Data was considered significant ifp< 0.05. 
All data is expressed as mean± standard error of the mean. 
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Results 
Blood Pressure Analysis 
Blood pressure data was collected from male and female Brown Norway Rats six 
months of age over a six week period of time. This analysis involved numerous 
experimental groups including animals exposed to the three major classes of calcium 
channel antagonists. The data presented in Figures 4-9 illustrate the impact of these 
antagonists on diastolic, systolic, and mean tail blood pressure for both sexes. 
Comparisons clearly indicate a statistically significant reduction in the diastolic, 
systolic, and mean tail blood pressure when compared to controls once specified 
groups of animals were injected with one of the three classes of calcium channel 
antagonists (P< .0001). The effect of these drugs on the blood pressure parameters 
studied for males are found in Figures 4-6 while the female data is expressed in 
Figures 7-9. It should be noted that the females receiving these antagonists had 
previously undergone surgery to remove their ovaries for a separate study and are 
utilized here for comparison purposes only. It is important to point out that the blood 
pressure parameters of the control, vehicle control, and ovarectomized groups are not 
statistically significant from each other. 
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Metabolic Study 
An analysis of skeletal turnover was conducted over a 29 day period in which the 
effects of calcium channel antagonists were compared between many metabolic 
parameters of aged male and female Brown Norway Rats. These parameters included 
body mass, dry skeletal mass, % dry skeletal mass, and numerous computer generated 
parameters for both the bone fluid and calcified skeletal compartments by monitoring 
the loss of 3H-tetracycline. Statistical comparisons were made between sexes and 
within each sex for all experimental groups studied. At the conclusion of 
3H-tetracycline collection the animals were sacrificed, weighed, dry skeletal mass 
determined, and% dry skeletal mass was calculated (Figures 10-12). The graphical 
presentation of body weight in Figure 10 clearly illustrates a statistical difference 
between the male and female rats (P< .0001). The statistical comparisons however 
did not suggest that the calcium channel antagonists had any adverse effect on the 
animals body weight. A similar phenomena is illustrated in Figure 11 as males 
clearly possess a significantly larger skeletal mass than females (P< .0001) without 
any apparent impact from the calcium channel antagonists. However, when the dry 
skeletal mass was normalized for body weight (% dry skeletal mass) a reversal was 
observed. Female rats have a significantly larger skeleton per gram of body tissue 
than their male counterparts (P< .0001 ). The data however still does not indicate any 
influence by calcium channel antagonists on skeletal mass in normal male and female 
Brown Norway Rats. It should be noted that the female vehicle control did express 
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statistical difference from the control for body weight and % dry skeletal mass 
(Figures 10 and 12). 
Utilizing Table Curve 2D Software to analyze the loss of 3H-tetracycline in 
urine demonstrated that a double exponential regression equation was the best fit 
equation for 100% of the experimental animals. This suggests that the turnover of 
3H-tetracycline is from two separate skeletal compartments, which will be referred to 
as the bone fluid and calcified skeletal compartments. This software provided 
regression data that is representative of the turnover rate for both skeletal 
compartments, the time required for these compartments to be depleted, and the 
ability to calculate the compartments relative size. These parameters can be further 
defined as follows: y-intercept, the uncomplicated rate oflabel loss at time zero with 
the bone pool fully labeled, 't, the time constant for depletion of the pool (theoretical 
x-intercept), (Cy-intercept ('t x 5))/2), the size of the compartment per gram of tissue, 
and the total pool size (pool size/ gram dry skeletal mass )(DSM). Figure 13 presents 
the effects of sex and calcium channel antagonists on the depletion rate of the bone 
fluid compartment. The statistical analysis indicated that only the male diltiazem and 
verapamil groups' differed significantly from their female counterparts (P< .05), but 
that a quickly depleted bone fluid compartment was the characteristic trend among 
males. No significance was detected within either sex between the controls and the 
experimental groups. The turnover rate of the bone fluid compartment (Figure 14) 
was greater in males than females. When compared to females the male vehicle 
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control, nifedipine, and verapamil treatment groups achieve statistical significance 
(P< .05), indicating a faster turnover rate than that found in female Brown Norway 
Rats. Comparisons made within sex expressed little significance, only the male 
nifedipine group was significant from its corresponding control (P< .05). A general 
trend did exist within the females potentially suggesting that calcium channel 
antagonists may increase the turnover rate of the bone fluid compartment. The bone 
fluid pool size/gm dry skeletal mass (Figure 15) displays sex differences only 
between the controls (P< .01). No significance exists between the male and female 
groups exposed to calcium channel antagonists clearly suggesting an impact of the 
drugs on the female pool size per gram of tissue. This is evident in that significance 
was detected in both the diltiazem and verapamil experimental groups when 
compared to the vehicle control (P< .05). Diltiazem's pool size was also significantly 
larger than the control group (P< .05). When you eliminate the body weight 
normalization and consider the total bone fluid pool size males are larger than their 
female counterparts (Figure 16). The total bone fluid pool size was significantly 
greater in the male controls (P< .05) and those males exposed to nifedipine (P<.05). 
Statistical comparisons made within the male groups did not provide significant 
differences even though verapamil's total pool size was obviously reduced. Female 
comparisons were identical to Figure 15 (pool size per gram of tissue), in that both 
diltiazem and verapamil possessed significantly larger pool sizes than the vehicle 
control (P< .05) and diltiazem was greater than the normal control (P< .05). It is 
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apparent that the calcium channel antagonist's, via some mechanism are influencing 
the total pool size in the female treatments when compared to controls. 
The pool depletion time for the calcified compartment can be seen in Figure 
17 and unlike the bone fluid compartment the time required to empty this 
compartment is basically the same between male and female Brown Norway Rats. 
The statistical analysis only indicated significance between the male and female 
verapamil groups (P< .05). The calcified compartment's resorption rate is 
significantly lower in males than females (Figure 18). Four of the five male treatment 
groups displayed a significant reduction in their resorption rate (P< .05). The only 
exception was the sexual comparison associated with diltiazem but even it followed 
the visual trend. No significance was found within male or female treatment groups, 
however the females were highlighted by lower resorptive rates for those groups 
exposed to calcium channel antagonists. The pool size per gram dry skeletal mass 
was significantly lower in three of the five male treatment groups ( control, nifedipine, 
and verapamil) when compared to their female counterparts (Figure 19). No statistical 
significance was detected within either sex following exposure to calcium channel 
antagonists. Figure 20 eliminates the body weight normalization and allows 
consideration of the total calcified pool size. The total labeled pool size was similar 
between the males and females with only one point of significance detected, between 
the vehicle control groups (P< .05) and none detected within either sex. 
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Figure 16. Effect of Sex and Calcium Channel Antagonists on the Total Bone Fluid Pool Size 
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Figure 18. Effect of Sex and Calcium Channel Antagonists on the Resorption Rate of the 
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Figure 19. Effect of Sex and Calcium Channel Antagonists on Calcified Pool Size/gm 
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Organ Isotope Extraction 
The amount of isotope collected from the bone fluid compartment in female 
Brown Norway Rats is graphically presented with the males allowing sexual 
comparisons but also by themselves allowing time interval comparisons due to the 
difference in isotope magnitude. The overall loss of3H-tetracycline from the bone 
fluid compartment ofrepresentative bones of both the axial and appendicular skeleton 
can be seen as well as the tissue utilized as a negative control in Figures 21-38. The 
graphical results indicate a significant decrease (P< .05) in the amount of isotope 
present in this pool across the experimental period within each sex and for both the 
controls and the animals exposed to nifedipine. This decreasing pattern in 3H-
tetracycline concentration varies between each time interval and/or skeletal bone 
type. The males possess a significantly larger pool of 3H-tetracycline (P< .05), 
undoubtedly due to their larger size. What should be noted is that nifedipine 
significantly (p< .05) increased the amount oflabel extracted from bones of the axial 
skeletal (Figures 21-28) than that of the appendicular skeleton (Figures 29-36). This 
effect is only detected in male comparisons except for the female parietal (Figure 21 
and 22) and the 2nd floating rib (Figures 27 and 28). The data for the negative control 
differs from that of skeletal tissue (Figure 37 and 38). The magnitude oflabel 
extracted from skeletal muscle was significantly less, sexual differences were 
detected only at 48hrs and nifedipine had no impact on the pool size. It is noteworthy 
that when comparing the isotope extracted from the negative control to the bones of 
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the axial skeleton that one gram of skeletal muscle is a lot more tissue than the 
specific bone studied. 
Once isotope stopped leeching from the bones in distilled H2O each bone was 
lyophilized and weighed. Each bone and the control tissue were exposed to a series 
of O.SM HCI extractions. The concentrations of isotope released from the calcified 
compartment as the inorganic portion of the skeletal tissue was dissolved can be seen 
in Figures 39-47. These figures clearly demonstrate that the calcified pool is 
significantly (P< .05) larger in males than females except for the atlas and 2nd lumbar 
vertebrae (Figures 40 and 41 ). The effects of time and nifedipine on the amount of 
isotope remaining in the calcified compartment were not statistically significant. The 
negative control (skeletal muscle) expressed no sex, time, or significant differences 
due to nifedipine (Figure 4 7). 
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Figure 24. Effect ofNifedipine on the Release of3H-Tetracycline from the Bone Fluid 
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Figure 28. Effect ofNifedipine on the Release of 3H-Tetracycline from the Bone Fluid 
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Figure 29. Effect of Sex and Nifedipine on the Release of3H-Tetracycline from the Bone 
Fluid Compartment of the Ulna in Aged Brown Norway Rats 
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Figure 30. Effect ofNifedipine on the Release of 3H-Tetracycline from the Bone 
Fluid Compartment of the Ulna in Aged Female Brown Norway Rats 
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Figure 32. Effect ofNifedipine on the Release of 3H-Tetracycline from the Bone Fluid 
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Figure 33. Effect of Sex and Nifedipine on the Release of 3H-Tetracycline from the 
Bone Fluid Compartment of the Tibia in Aged Brown Norway Rats 
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Figure 34. Effect ofNifedipine on the Release of 3H-Tetracycline from the Bone Fluid 
Compartment of the Tibia in Aged Female Brown Norway Rats 
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Figure 35. Effect of Sex and Nifedipine on the Release of 3H-Tetracycline from the Bone 
Fluid Compartment of the Femur in Aged Brown Norway Rats 
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Figure 36. Effect ofNifedipine on the Release of 3H-Tetracycline from the Bone Fluid 
Compartment of the Femur in Aged Female Brown Norway Rats 
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Figure 37. Effect of Sex and Nifedipine on the Release of 3H-Tetracycline from 
Skeletal Muscle in Aged Brown Norway Rats 
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Figure 38. Effect ofNifedipine on the Release of3H-Tetracycline from the Skeletal Muscle in 
Aged Female Brown Norway Rats 
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Figure 39. Effect of Sex and Nifedipine on 3H-Tetracycline Concentration in the 
Calcified Bone Compartment of the Parietal in Aged Brown Norway Rats 
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Figure 40. Effect of Sex and Nifedipine on 3H-Tetracycline Concentration in the 
Calcified Bone Compartment of the Atlas in Aged Brown Norway Rats 
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Figure 41. Effect of Sex and Nifedipine on the 3H-Tetracycline Concentration in the 
Calcified Bone Compartment of the 2nd Lumbar Vertebrae in Aged Brown 
Norway Rats 
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Figure 43. Effect of Sex and Nifedipine on 3H-Tertracycline Concentration in the 
Calcified Bone Compartment of the Ulna in Aged Brown Norway Rats 
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Figure 44. Effect of Sex and Nifedipine on 3H-Tetracycline Concentration in the 
Calcified Bone Compartment of the Humerus in Aged Brown Norway Rats 
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Figure 45. Effect of Sex and Nifedipine on 3H-Tetracycline Concentration in the 
Calcified Bone Compartment of the Tibia in Aged Brown Norway Rats 
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Figure 46. Effect of Sex and Nifedipine on 3H-Tetracycline Concentration in the 
Calcified Bone Compartment of the Femur in Aged Brown Norway Rats 
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Figure 47. Effect of Sex and Nifedipine on 3H-Tetracycline Concentration in the 
Skeletal Muscle in Aged Brown Norway Rats 
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Discussion 
Blood Pressure Analysis 
Blood pressure was monitored in both male and female Brown Norway Rats six 
months of age following their exposure to calcium channel antagonists ( diltiazem, 
nifedipine, or verapamil), compounds routinely prescribed for the treatment of high 
blood pressure in humans. This analysis clearly illustrates the impact of these drugs 
on male and female blood pressure when continuously given over a three week period 
which indicates that as the plasma level of calcium channel antagonists are increased 
and maintained, blood pressure is reduced accordingly. This observation has been 
routinely demonstrated in rodent models (Imai et al., 1994). The results indicate an 
immediate significant decrease in systolic, diastolic, and mean tail blood pressure for 
all groups receiving an antagonist (Figures 4-9) just as Waeber et al. (1985) has 
demonstrated for verapamil. The female data (DeMoss, unpublished) was extracted 
from a previous study focusing on a reduction in circulating levels of estrogen in rats 
that had been ovariectomized. The female experimental groups illustrate the same 
statistical findings as their male counterparts. Since the female control and 
ovariectomized groups were not significant from each other, these groups were 
utilized for comparison purposes instead ofrepeating the study with non-
ovariectomized animals. The vehicle control also provides evidence that the solvent 
used to dissolve the drugs is not responsible for the significant drop in blood pressure 
characteristic when the animals were exposed to calcium channel antagonists. 
Together the male and female data suggest that the concentrations of calcium channel 
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antagonists utilized during the experimental period for both sexes of Brown Norway 
Rats were sufficient to induce a significant reduction in cardiovascular activity. 
Metabolic Study 
Analysis of skeletal turnover from this research allowed a comparison of the 
effects of calcium channel antagonists on aged male and female Brown Norway Rats 
to be made through the utilization of the in-vivo 3H-tetracycline Rat Model. This 
methodology allows monitoring of3H-tetracycline release from the skeleton of 
exposed animals in order to demonstrate bone matrix resorption through renal 
activity. This physiologically relevant marker is considered to be a direct indicator of 
bone resorption and has been routinely used for whole animal studies (Klein, 1983). 
Utilization of this model allowed an examination of the following metabolic 
parameters: rate of bone resorption, pool depletion time, 3H-tetracycline pool size per 
gram of dry skeletal mass, and the total 3H-tetracycline pool size. When the metabolic 
experiment was terminated on day 29, body weight and dry skeletal mass were also 
obtained and % dry skeletal mass calculated. 
Though the data for body weight (Figure 10), dry skeletal mass (Figure 11 ), and 
% dry skeletal mass (Figure 12) clearly express a sex difference, they also indicate 
that calcium channel antagonists do not influence these easily obtainable parameters. 
The sex differences were expected and demonstrate hallmark characteristic 
differences between male and female rats (DeMoss, 1998). Not expected were the 
statistical differences observed between the female control and vehicle control groups 
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for body weight and% dry mass. These differences were most likely due to the 
arrival time of animals from Harlan since the animals placed in the vehicle control 
group were obviously smaller when they were received and as a result were 
significantly smaller at the onset of experimentation. 
As expected the greater overall size of the male animals (Figure 10) resulted in 
larger skeletons than their female counterparts (Figure 11 ). Larger animals require a 
larger skeleton to support their greater mass. However, when the data was 
normalized for body weight the females displayed a significantly larger skeleton per 
gram of body tissue than their male counterparts (Figure 12). This greater percentage 
has been routinely attributed to greater demands placed on the female skeleton during 
the bearing and rearing of young, factors males are not faced with (DeMoss, 1998). 
This would suggest that the size of the rat skeleton is not entirely correlated with 
body weight (Wright et al., 2000). 
The metabolic parameters of skeletal activity for the bone fluid compartment in 
male Brown Norway Rats exposed to calcium channel antagonists suggest no 
apparent physiological effect. No statistical significance was found in the time 
required for the pool to be depleted (Figure 13). Limited significance was detected 
within male treatment groups for the turnover rate of the bone fluid compartment 
(Figure 14). Only the group of animals exposed to nifedipine showed any apparent 
stimulation in metabolic activity. Since the x and y-intercepts were not significantly 
affected by the drugs in aged male Brown Norway Rats, it only makes sense that the 
metabolically active pool size per gram of dry skeletal mass (Figure 15) and the total 
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metabolically active pool (Figure 16) would show no significant changes between 
treatment groups. These findings suggest that calcium channel antagonists had no 
apparent effect on the physiological activity of the male bone fluid compartment. 
However, the metabolic parameters of skeletal activity for the bone fluid 
compartment in female Brown Norway Rats exposed to calcium channel antagonists 
suggests an increase in the turnover of this compartment consistent with previous 
work published by DeMoss and Wright 1997, 2000. No statistical significance was 
found in the time required for the pool to be depleted, (Figure 13). There was 
however considerable variability within the data. The turnover rate of the bone fluid 
compartment did not present any statistical significance but did demonstrate a 
potential drug induced effect when compared to the controls (Figure 14). One would 
assume that ifx and y-intercepts were not altered, then no apparent effects should be 
seen in either the metabolically active pool size per gram of dry skeletal mass (Figure 
15) or the total metabolically active bone fluid pool (Figure 16). This is not the case 
because the females exposed to the calcium channel antagonists all demonstrated an 
increase in the metabolically active pool size per gram dry skeletal mass and total 
metabolically active bone fluid pool. This can only be accounted for by the 
nonsignificant trend (increase) observed in the turnover rate of Figure 14. The groups 
of female animals exposed to the calcium channel antagonists diltiazem and 
verapamil demonstrated a significant increase in pool size per gram dry skeletal mass 
during the experimental period due to the apparent increase in the turnover rate of the 
bone fluid compartment. 
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With regards to sexual differences, male Brown Norway Rats appear to have a 
greater turnover rate (Figure 14) and thus the time required for them to deplete the 
bone fluid compartment (Figure 13) is quicker than that of female Brown Norway 
Rats. The overall size of the bone fluid compartment in males is significantly greater 
than that of females (Figure 16). This makes sense because males are larger animals 
than females and you would expect them to have a larger bone fluid compartment. 
The only potential exception to this conclusion is the impact of verapamil on the male 
bone fluid compartment. The significance of verapamil decreasing the male x-
intercept and its resulting influence on pool size per gram of dry skeletal mass as well 
as total pool size will require further investigation. 
If the drug dosage was increased in males, would results similar to that of females 
occur in the bone fluid compartment? It is evident, however, that the dosage utilized 
in this study was great enough to impact the cardiovascular system, in both males and 
females, significantly lowering blood pressure. 
The metabolic parameters of skeletal activity for the calcified compartment in 
male and female Brown Norway Rats exposed to calcium channel antagonists suggest 
no apparent physiological effect. No statistical significance was found between 
treatment groups for the time required to deplete the pool (Figure 17) or the bone 
resorption rate (Figure 18). Since the x and y-intercepts were not significantly altered 
by the drugs in aged male and female Brown Norway Rats it only makes sense that 
the metabolically active pool size per gram dry skeletal mass (Figure 19) and the total 
metabolically active calcified pool (Figure 20) possessed no significant differences 
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between treatment groups. These findings would indicate that calcium channel 
antagonists had no apparent effect on the physiologic activity of the male and female 
calcified bone compartment. It is probably worth mentioning that the female 
treatment groups exposed to calcium channel antagonists had a lower bone resorption 
rate. This decrease was not significant and did not impart any impact on the pool size 
per gram dry skeletal mass or total pool size. This appears important because data 
previously collected in female animals that have undergone ovariectomy or had 
hypertension were significantly effected (DeMoss, unpublished and Wight and 
DeMoss 2000). 
With regard to sexual differences, female Brown Norway Rats have a 
significantly greater bone resorption rate than their male counterparts (Figure 18). 
The time required to empty the pool appears to be the same between males and 
females (Figure 17) but the metabolically active calcified pool size per gram dry 
skeletal mass is significantly greater in females (Figure 19). Their basal level of 
resorption is greater than males and as a result the normalized pool per gram is larger 
than their male counterparts. When the body weight normalization is removed, 
(Figure 20) the total metabolically active calcified pool is not significant between 
males and females. This probably reflects the fact that the animals were injected with 
a common amount of isotope but more importantly that the rate of bone formation in 
males and females is apparently similar in aged Brown Norway Rats in order for the 
total calcified pool size not to be statistically significant. 
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The data suggests that the calcium channel antagonists employed in this study are 
not having quite the effects on the calcified compartment of males and females as 
they are on the bone fluid compartment of the normal females. The treatment of the 
candidate calcium channel antagonists (diltiazem, nifedipine, and verapamil) does not 
demonstrate a clear significant impact on the skeletal physiology, of the tested 
metabolic parameters, in either male or female aged Brown Norway rats. The 
clearest difference in any of the studied parameters appears to be of a sexual nature, 
indicating that sex most definitely has an impact on the skeletons physiological 
mechanisms. However the fact that the calcium channel antagonists increase the 
turnover rate of the bone fluid compartment and that this results in significant 
changes in the pool size per gram and total bone fluid pool size is obviously very 
significant. The fact that these same drugs lower the resorption rate of the calcified 
compartment but did not significantly influence pool size is of particular interest in 
the lab. It has already been demonstrated that females that have been ovariectomized 
and treated with calcium channel blockers have lowered resorption rates than those 
females that were ovariectomized but not treated with calcium channel antagonists 
(DeMoss, unpublished). 
Organ Isotope Extraction 
In an attempt to study the bone fluid and calcified compartments and support the 
conclusions drawn from the metabolic procedures with regard to the existence of both 
a labile (bone fluid compartment) and stable (calcified compartment) pool of calcium 
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organ isotope extraction was utilized. The design of the study allowed me to make 
sexual comparisons and study the impact of one of the classes of calcium channel 
antagonists (1,4-dihydropyridines,(nifedipine)) on these pools. 
As would have been expected, the bone fluid and calcified pool size was 
statistically greater in males than in females. Based on physical size of the animals 
utilized, one would naturally expect that exposing these animals to an isotope with an 
affinity for skeletal tissue, that more isotope would be taken up by the skeletal 
compartments of the larger males. The data also clearly suggests that isotope not 
deposited into the calcified matrix can be leeched out and significantly decreases over 
time intervals studied for both males and females. Since the amount of isotope is 
decreasing does that suggest that isotope enters into the bone fluid compartment and 
then enters the caicified matrix or does it enter and then just wash out with time? 
Since a significant concentration of isotope is detected in the calcified matrix that 
couldn't be extracted with distilled water, it is concluded that the isotope enters into 
this labile pool and associates itself with elements that could be deposited in active 
mineralization during the labeling period. Thus, it is possible that some of the isotope 
may never have been deposited into the matrix and as a result is in a readily 
exchangeable pool of elements that can be removed from the bone fluid compartment 
and excreted in the urine. The data does not suggest that the size of the calcified 
compartment is increasing as isotope moves from the bone fluid compartment into the 
calcified compartment after the injections have stopped. This could be due to the fact 
that as some of the isotope moves into active sites for deposition that some isotope is 
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being resorbed from other sites and excreted. This would support data obtained from 
the calcified compartment in that basically no statistical significance exists between 
the time intervals of sacrifice. There appears to be no distinguishable physiological 
trend in bones selected from either the axial or appendicular skeleton. It would 
appear that the calcified compartment for these individual bones whether they are 
weight-bearing or nonweight-bearing only display what is routinely described as 
individuality as suggested by Wright et al. and Geng et al. in 2000. 
The calcium channel antagonist, nifedipine, utilized in the study appears to 
influence the physiological activity of the skeleton. This compound exerts no 
apparent impact on the amount of isotope present in the calcified compartment while 
significantly altering the uptake or release of the isotope from the bone fluid 
compartment. The impact is best seen in the bones of the axial skeleton (Figures 21-
28) and is more extensively seen in males than females. Thus, it would appear that 
injecting animals with nifedipine following the labeling period is affecting isotope 
release or some how stimulating increased uptake. Isotope release does significantly 
decrease over time while the animal is receiving nifedipine, since the amount present 
in the calcified compartment is not significantly increased, this would either suggest 
increased calcified remodeling or increased transport of the isotope into the bone fluid 
compartment at the onset of the nifedipine exposure while significant levels of the 
isotope are still circulating. 
It would appear that each bone has its own physiological parameters or 
individuality making each of these organs slightly different from other members of 
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the skeletal network. The data also would suggest that bones of the axial skeleton 
which possess a greater percentage of trabecular bone per gram of skeletal mass have 
their ability to exchange isotope altered following exposure to the calcium channel 
antagonist, nifedipine. The fact that bones of the axial skeleton were the most 
influenced was not unexpected since Geng et al. 2000 had already indicated that the 
metabolic rate of bones from the axial skeleton had a faster turnover rate than bones 
from the appendicular skeleton. Further experimentation that includes other calcium 
channels may yield more conclusive evidence about the effects that these drugs have 
on the bones physiology. 
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